Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

2.

Functional characterisation of receptors for cysteinyl leukotrienes in smooth muscle.

Jonsson EW.

Acta Physiol Scand Suppl. 1998 Mar;641:1-55. Review.

PMID:
9597121
3.

Clinical experience with MK-571. A potent and specific LTD4 receptor antagonist.

Margolskee DJ.

Ann N Y Acad Sci. 1991;629:148-56. Review. No abstract available.

PMID:
1659276
4.

The preclinical and clinical pharmacology of SK&F 104353, a potent and selective peptidoleukotriene receptor antagonist.

Torphy TJ, Faiferman I, Gleason JG, Hall RF, Lewis MA, Broom C, Helfrich HM, Newton JF, Hay DW.

Ann N Y Acad Sci. 1991;629:157-67. Review. No abstract available.

PMID:
1659277
5.

Pharmacology of peptide leukotriene receptor antagonists.

Aharony D, Krell RD.

Ann N Y Acad Sci. 1991;629:125-32. Review. No abstract available.

PMID:
1952544
6.

The development of new antileukotriene drugs: specific leukotriene D4 antagonists and 5-lipoxygenase inhibitors.

Rokach J, Young RN.

Adv Exp Med Biol. 1989;259:75-108. Review. No abstract available.

PMID:
2560345
7.

The emergence of potent and selective peptide leukotriene receptor antagonists.

Krell RD.

Pulm Pharmacol. 1989;2(1):27-31. Review.

PMID:
2562468
8.

New developments concerning leukotriene antagonists: a review.

Musser JH, Kreft AF, Lewis AJ.

Agents Actions. 1986 Jun;18(3-4):332-41. Review.

PMID:
3529882
9.

Signal transduction processes for the LTD4 receptor.

Crooke ST, Sarau H, Saussy D, Winkler J, Foley J.

Adv Prostaglandin Thromboxane Leukot Res. 1990;20:127-37. Review. No abstract available.

PMID:
2169177

Supplemental Content

Support Center